Myeloid regulatory cells in tumor spreading and metastasis

Immunobiology

Volumn 220, Issue 2, 2015, Pages 236-242

  Keskinov, Anton A ^a   Shurin, Michael R ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Cancer; Immunosuppression; MDSC; Metastasis; Tumor microenvironment

Indexed keywords

CHEMOKINE; CYTOKINE; GROWTH FACTOR; PROTEINASE;

B LYMPHOCYTE; BASEMENT MEMBRANE; BLOOD VESSEL; BONE MARROW CELL; CANCER CELL; CANCER IMMUNOLOGY; CANCER INHIBITION; CELL ADHESION; CELL COMMUNICATION; CELL EXPANSION; CELL FUNCTION; CELL INTERACTION; CELL SPREADING; CELL SURVIVAL; DENDRITIC CELL; EXTRACELLULAR MATRIX; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOBIOLOGY; INFLAMMATION; LYMPH VESSEL; MACROPHAGE; METASTASIS; MYELOID REGULATORY CELL; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL NICHE; STROMA CELL; TROPISM; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; ANIMAL; DISEASE COURSE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR INVASION;

ANIMALS; DISEASE PROGRESSION; HUMANS; IMMUNE TOLERANCE; IMMUNOMODULATION; MYELOID CELLS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84992008656     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2014.07.017     Document Type: Review

References (83)

1. Abrams S.I., Waight J.D. Identification of a G-CSF-granulocytic MDSC axis that promotes tumor progression. Oncoimmunology 2012, 1:550.
2. Angelini G., Gardella S., Ardy M., Ciriolo M.R., Filomeni G., Di Trapani G., Clarke F., Sitia R., Rubartelli A. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:1491.
3. Bacac M., Stamenkovic I. Metastatic cancer cell. Annu. Rev. Pathol. 2008, 3:221.
4. Boutte A.M., Friedman D.B., Bogyo M., Min Y., Yang L., Lin P.C. Identification of a myeloid-derived suppressor cell cystatin-like protein that inhibits metastasis. FASEB J. 2011, 25:2626.
5. Brandau S., Moses K., Lang S. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins?. Semin. Cancer Biol. 2013, 23:171.
6. Bunt S.K., Clements V.K., Hanson E.M., Sinha P., Ostrand-Rosenberg S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J. Leukoc. Biol. 2009, 85:996.
7. Castellani P., Angelini G., Delfino L., Matucci A., Rubartelli A. The thiol redox state of lymphoid organs is modified by immunization: role of different immune cell populations. Eur. J. Immunol. 2008, 38:2419.
8. Chalmin F., Ladoire S., Mignot G., Vincent J., Bruchard M., Remy-Martin J.P., Boireau W., Rouleau A., Simon B., Lanneau D., De Thonel A., Multhoff G., Hamman A., Martin F., Chauffert B., Solary E., Zitvogel L., Garrido C., Ryffel B., Borg C., Apetoh L., Rebe C., Ghiringhelli F. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J. Clin. Invest. 2010, 120:457.
9. Cheng P., Corzo C.A., Luetteke N., Yu B., Nagaraj S., Bui M.M., Ortiz M., Nacken W., Sorg C., Vogl T., Roth J., Gabrilovich D.I. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 2008, 205:2235.
10. Choi J., Suh B., Ahn Y.-O., Kim T.M., Lee J.-O., Lee S.-H., Heo D.S. CD15+/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function. Tumour Biol. 2012, 33:121.
11. Corzo C.A., Condamine T., Lu L., Cotter M.J., Youn J.I., Cheng P., Cho H.I., Celis E., Quiceno D.G., Padhya T., McCaffrey T.V., McCaffrey J.C., Gabrilovich D.I. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 2010, 207:2439.
12. Deng J., Liu Y., Lee H., Herrmann A., Zhang W., Zhang C., Shen S., Priceman S.J., Kujawski M., Pal S.K., Raubitschek A., Hoon D.S., Forman S., Figlin R.A., Liu J., Jove R., Yu H. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell 2012, 21:642.
13. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 2009, 58:49.
14. Dilek N., Vuillefroy de Silly R., Blancho G., Vanhove B. Myeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance. Front. Immunol. 2012, 3:208.
15. Engels B., Rowley D.A., Schreiber H. Targeting stroma to treat cancers. Semin. Cancer Biol. 2012, 22:41.
16. Erler J.T., Bennewith K.L., Cox T.R., Lang G., Bird D., Koong A., Le Q.T., Giaccia A.J. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009, 15:35.
17. Eruslanov E., Neuberger M., Daurkin I., Perrin G.Q., Algood C., Dahm P., Rosser C., Vieweg J., Gilbert S.M., Kusmartsev S. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int. J. Cancer 2012, 130:1109.
18. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3:453.
19. Gabitass R.F., Annels N.E., Stocken D.D., Pandha H.A., Middleton G.W. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol. Immunother. 2011, 60:1419.
20. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162.
21. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253.
22. Gao D., Joshi N., Choi H., Ryu S., Hahn M., Catena R., Sadik H., Argani P., Wagner P., Vahdat L.T., Port J.L., Stiles B., Sukumar S., Altorki N.K., Rafii S., Mittal V. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 2012, 72:1384.
23. Granot Z., Henke E., Comen E.A., King T.A., Norton L., Benezra R. Tumor entrained neutrophils inhibit seeding in the premetastatic lung. Cancer Cell 2011, 20:300.
24. Gupta G.P., Massague J. Cancer metastasis: building a framework. Cell 2006, 127:679.
25. Gutkin D.W., Shurin M.R. Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunol. Immunother. 2014, 63:45.
26. Hanson E.M., Clements V.K., Sinha P., Ilkovitch D., Ostrand-Rosenberg S. Myeloid-derived suppressor cells down-regulate l-selectin expression on CD4+ and CD8+ T cells. J. Immunol. 2009, 183:937.
27. Hirai H., Zhang P., Dayaram T., Hetherington C.J., Mizuno S., Imanishi J., Akashi K., Tenen D.G. C/EBPbeta is required for 'emergency' granulopoiesis. Nat. Immunol. 2006, 7:732.
28. Hiratsuka S., Watanabe A., Aburatani H., Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat. Cell Biol. 2006, 8:1369.
29. Hoechst B., Ormandy L.A., Ballmaier M., Lehner F., Kruger C., Manns M.P., Greten T.F., Korangy F. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology 2008, 135:234.
30. Huang A., Zhang B., Wang B., Zhang F., Fan K.X., Guo Y.J. Increased CD14(+)HLA-DR (-/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol. Immunother. 2013, 62:1439.
31. Huang S.M., Li J., Harari P.M. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol. Cancer Ther. 2002, 1:507.
32. Ichikawa M., Williams R., Wang L., Vogl T., Srikrishna G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol. Cancer Res. 2011, 9:133.
33. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239.
34. Kim S., Takahashi H., Lin W.W., Descargues P., Grivennikov S., Kim Y., Luo J.L., Karin M. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457:102.
35. Kim Y.S., Kim Y.J., Lee J.M., Kim E.K., Park Y.J., Choe S.K., Ko H.J., Kang C.Y. Functional changes in myeloid-derived suppressor cells (MDSCs) during tumor growth: FKBP51 contributes to the regulation of the immunosuppressive function of MDSCs. J. Immunol. 2012, 188:4226.
36. Kowanetz M., Wu X., Lee J., Tan M., Hagenbeek T., Qu X., Yu L., Ross J., Korsisaari N., Cao T., Bou-Reslan H., Kallop D., Weimer R., Ludlam M.J., Kaminker J.S., Modrusan Z., van Bruggen N., Peale F.V., Carano R., Meng Y.G., Ferrara N. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:21248.
37. Lechner M.G., Megiel C., Russell S.M., Bingham B., Arger N., Woo T., Epstein A.L. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines. J. Transl. Med. 2011, 9:90.
38. LeCouter J., Zlot C., Tejada M., Peale F., Ferrara N. Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:16813.
39. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat. Rev. Immunol. 2007, 7:678.
40. Li H., Han Y., Guo Q., Zhang M., Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 2009, 182:240.
41. Li S., Sun Y., Gao D. Role of the nervous system in cancer metastasis. Oncol. Lett. 2013, 5:1101.
42. Liu C., Yu S., Kappes J., Wang J., Grizzle W.E., Zinn K.R., Zhang H.G. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 2007, 109:4336.
43. Liu C.Y., Wang Y.M., Wang C.L., Feng P.H., Ko H.W., Liu Y.H., Wu Y.C., Chu Y., Chung F.T., Kuo C.H., Lee K.Y., Lin S.M., Lin H.C., Wang C.H., Yu C.T., Kuo H.P. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14(-)/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 2010, 136:35.
44. Lu T., Ramakrishnan R., Altiok S., Youn J.I., Cheng P., Celis E., Pisarev V., Sherman S., Sporn M.B., Gabrilovich D. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J. Clin. Invest. 2011, 121:4015.
45. Marchesi F., Piemonti L., Mantovani A., Allavena P. Molecular mechanisms of perineural invasion, a forgotten pathway of dissemination and metastasis. Cytokine Growth Factor Rev. 2010, 21:77.
46. Marigo I., Bosio E., Solito S., Mesa C., Fernandez A., Dolcetti L., Ugel S., Sonda N., Bicciato S., Falisi E., Calabrese F., Basso G., Zanovello P., Cozzi E., Mandruzzato S., Bronte V. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010, 32:790.
47. Marigo I., Dolcetti L., Serafini P., Zanovello P., Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 2008, 222:162.
48. Meyer C., Cagnon L., Costa-Nunes C.M., Baumgaertner P., Montandon N., Leyvraz L., Michielin O., Romano E., Speiser D.E. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol. Immunother. 2014, 63:247.
49. Nagaraj S., Nelson A., Youn J.I., Cheng P., Quiceno D., Gabrilovich D.I. Antigen-specific CD4(+) T cells regulate function of myeloid-derived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res. 2012, 72:928.
50. Obermajer N., Muthuswamy R., Lesnock J., Edwards R.P., Kalinski P. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011, 118:5498.
51. Obermajer N., Muthuswamy R., Odunsi K., Edwards R.P., Kalinski P. PGE(2)-induced CXCL12 production and CXCR4 expression controls the accumulation of human MDSCs in ovarian cancer environment. Cancer Res. 2011, 71:7463.
52. Oh W.J., Gu C. The role and mechanism-of-action of Sema3E and Plexin-D1 in vascular and neural development. Semin. Cell Dev. Biol. 2013, 24:156.
53. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr. Opin. Genet. Dev. 2008, 18:11.
54. Peiyuan Zhu Y.V.S., Galina V., Shurin M. Analysis of Myeloid-Derived Suppressor Cells in Patients with Cancer 2013, Springer, New York, 707 pp.
55. Poschke I., Mougiakakos D., Hansson J., Masucci G.V., Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 2010, 70:4335.
56. Psaila B., Lyden D. The metastatic niche: adapting the foreign soil. Nat. Rev. Cancer 2009, 9:285.
57. Rodriguez P.C., Ernstoff M.S., Hernandez C., Atkins M., Zabaleta J., Sierra R., Ochoa A.C. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 2009, 69:1553.
58. Sceneay J., Chow M.T., Chen A., Halse H.M., Wong C.S., Andrews D.M., Sloan E.K., Parker B.S., Bowtell D.D., Smyth M.J., Moller A. Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 2012, 72:3906.
59. Sceneay J., Smyth M.J., Moller A. The pre-metastatic niche: finding common ground. Cancer Metastasis Rev. 2013, 32:449.
60. Schmid M.C., Varner J.A. Myeloid cells in tumor inflammation. Vasc. Cell 2012, 4:14.
61. Semenza G.L. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 2012, 33:207.
62. Serafini P. Editorial: PGE2-producing MDSC: a role in tumor progression?. J. Leukoc. Biol. 2010, 88:827.
63. Serafini P., Meckel K., Kelso M., Noonan K., Califano J., Koch W., Dolcetti L., Bronte V., Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 2006, 203:2691.
64. Sevko A., Umansky V. Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves. J. Cancer 2013, 4:3.
65. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 2007, 117:1155.
66. Sinha P., Clements V.K., Bunt S.K., Albelda S.M., Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 2007, 179:977.
67. Sinha P., Okoro C., Foell D., Freeze H.H., Ostrand-Rosenberg S., Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 2008, 181:4666.
68. Smith H.A., Kang Y. The metastasis-promoting roles of tumor-associated immune cells. J. Mol. Med. (Berl.) 2013, 91:411.
69. Solito S., Falisi E., Diaz-Montero C.M., Doni A., Pinton L., Rosato A., Francescato S., Basso G., Zanovello P., Onicescu G., Garrett-Mayer E., Montero A.J., Bronte V., Mandruzzato S. A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells. Blood 2011, 118:2254.
70. Srivastava M.K., Sinha P., Clements V.K., Rodriguez P., Ostrand-Rosenberg S. Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res. 2010, 70:68.
71. Srivastava M.K., Zhu L., Harris-White M., Huang M., St John M., Lee J.M., Salgia R., Cameron R.B., Strieter R., Dubinett S., Sharma S. Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer. Immunotargets Ther. 2012, 2012:7.
72. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl. Cancer Inst. 1998, 90:1609.
73. Toh B., Wang X., Keeble J., Sim W.J., Khoo K., Wong W.C., Kato M., Prevost-Blondel A., Thiery J.P., Abastado J.P. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol. 2011, 9:e1001162.
74. Vuk-Pavlovic S., Bulur P.A., Lin Y., Qin R., Szumlanski C.L., Zhao X., Dietz A.B. Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate 2010, 70:443.
75. Weide B., Martens A., Zelba H., Stutz C., Derhovanessian E., Di Giacomo A.M., Maio M., Sucker A., Schilling B., Schadendorf D., Buttner P., Garbe C., Pawelec G. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells. Clin. Cancer Res. 2014, 20:1601.
76. Xiang X., Poliakov A., Liu C., Liu Y., Deng Z.B., Wang J., Cheng Z., Shah S.V., Wang G.J., Zhang L., Grizzle W.E., Mobley J., Zhang H.G. Induction of myeloid-derived suppressor cells by tumor exosomes. Int. J. Cancer 2009, 124:2621.
77. Yan H.H., Pickup M., Pang Y., Gorska A.E., Li Z., Chytil A., Geng Y., Gray J.W., Moses H.L., Yang L. Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res. 2010, 70:6139.
78. Yang J., Weinberg R.A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 2008, 14:818.
79. Yang L., DeBusk L.M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., Matrisian L.M., Carbone D.P., Lin P.C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6:409.
80. Youn J.I., Collazo M., Shalova I.N., Biswas S.K., Gabrilovich D.I. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J. Leukoc. Biol. 2012, 91:167.
81. Youn J.I., Gabrilovich D.I. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol. 2010, 40:2969.
82. Zhang B., Wang Z., Wu L., Zhang M., Li W., Ding J., Zhu J., Wei H., Zhao K. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLOS ONE 2013, 8:e57114.
83. Zhong H., Gutkin D.W., Han B., Ma Y., Keskinov A.A., Shurin M.R., Shurin G.V. Origin and pharmacological modulation of tumor-associated regulatory dendritic cells. Int. J. Cancer 2014, 134:2633.